Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Liu Z, Wang C, Chen X, Zhu J, Sun X, Xia Q, Lu Z, Qiao J, Zhou Y, Wang H, Wang Y, Yan M. Liu Z, et al. Among authors: yan m. Eur J Cancer. 2022 Apr;165:157-168. doi: 10.1016/j.ejca.2022.01.022. Epub 2022 Feb 27. Eur J Cancer. 2022. PMID: 35235873 Free article. Clinical Trial.
Dysregulated expression of dicer and drosha in breast cancer.
Yan M, Huang HY, Wang T, Wan Y, Cui SD, Liu ZZ, Fan QX. Yan M, et al. Pathol Oncol Res. 2012 Apr;18(2):343-8. doi: 10.1007/s12253-011-9450-3. Epub 2011 Sep 7. Pathol Oncol Res. 2012. PMID: 21898071 Free article.
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Zhang P, et al. Among authors: yan m. Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8. Epub 2017 Feb 11. Lancet Oncol. 2017. PMID: 28209298 Clinical Trial.
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J, Wang S, Wang Y, Wang X, Wang H, Feng J, Zhang Q, Sun T, Ouyang Q, Yin Y, Liu Y, Geng C, Yan M, Jiang Z. Li J, et al. Among authors: yan m. Oncologist. 2017 Nov;22(11):1333-1338. doi: 10.1634/theoncologist.2017-0088. Epub 2017 Aug 10. Oncologist. 2017. PMID: 28798274 Free PMC article.
Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
Zheng Y, Yang X, Yan C, Feng R, Sah BK, Yang Z, Zhu Z, Liu W, Xu W, Ni Z, Beeharry MK, Hua Z, Yan M, Zhu Z, Li C. Zheng Y, et al. Among authors: yan m, yan c. Eur J Cancer. 2020 May;130:12-19. doi: 10.1016/j.ejca.2020.02.013. Epub 2020 Mar 11. Eur J Cancer. 2020. PMID: 32171104 Free article. Clinical Trial.
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
Yang F, Huang X, Sun C, Li J, Wang B, Yan M, Jin F, Wang H, Zhang J, Fu P, Zeng T, Wang J, Li W, Li Y, Yang M, Li J, Wu H, Fu Z, Yin Y, Jiang Z. Yang F, et al. Among authors: yan m. BMC Cancer. 2020 Mar 29;20(1):255. doi: 10.1186/s12885-020-6639-4. BMC Cancer. 2020. PMID: 32223744 Free PMC article.
6,673 results